Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer

Annals of Surgical Oncology

Volumn 22, Issue 7, 2015, Pages 2416-2423

  Cooper, Amanda B ^a   Slack, Rebecca ^b   Fogelman, David ^b   Holmes, Holly M ^b   Petzel, Maria ^b   Parker, Nathan ^b   Balachandran, Aparna ^b   Garg, Naveen ^b   Ngo Huang, An ^b   Varadhachary, Gauri ^b   Evans, Douglas B ^c   Lee, Jeffrey E ^b   Aloia, Thomas ^b   Conrad, Claudius ^b   Vauthey, Jean Nicolas ^b   Fleming, Jason B ^b   Katz, Matthew H G ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADIPOSE TISSUE; ADJUVANT CHEMORADIOTHERAPY; ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; RACE; SARCOPENIA; SKELETAL MUSCLE; SMOKING; SUBCUTANEOUS FAT; TREATMENT OUTCOME; WEIGHT REDUCTION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BODY WEIGHT; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; BODY WEIGHT; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOPENIA; SURVIVAL RATE;

EID: 84930476950     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4285-2     Document Type: Article

References (35)

1. Rosenberg IH, Roubenoff R. Stalking sarcopenia. Ann Intern Med. 1995;123:727–8.
2. Peng P, Hyder O, Firoozmand A, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:1478–86.
3. Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Sympt Manag. 2012;44:181–91.
4. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–9.
5. Di Sebastiano KM, Yang L, Zbuk K, et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr. 2013;109:302–12.
6. Jacquillat C, Baillet F, Auclerc G, et al. Neoadjuvant chemotherapy of breast cancer. Drugs Exp Clin Res. 1986;12:147–52.
7. Scholl SM, Asselain B, Palangie T, et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer. 1991;27:1668–71.
8. Mehta VK, Poen J, Ford J, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum. 2001;44:52–8.
9. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J ClinOncol. 2006;24:650–5.
10. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165–74.
11. Walsh TN, Grennell M, Mansoor S, Kelly A. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus. 2002;15:121–4.
12. Del Fabbro E, Parsons H, Warneke CL, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17:1240–5.
13. Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr (Edinburgh). 2012;31:74–7.
14. Clark W, Siegel EM, Chen YA, et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg. 2013;216:1070–81.
15. Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014. J NatlComp Cancer Netw. 2014;12:1083–93.
16. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487–95.
17. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.
18. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935–49; discussion 949–50.
19. Evans DB, Lee JE, Tamm EP, Pisters PWT. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In: Fischer J, editor Master of surgery. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1299–317.
20. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
21. Mehta CR, Patel NR. A network algorithm for performing Fisher’s exact test in r x c contingency tables. J Am Stat Assoc. 1983;78:427–34.
22. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
23. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.
24. Lausen B, Sauerbrei W, Schumacher V. Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales. Contr Stat. 1994:483–96.
25. Shen W, Punyanitya M, Wang Z, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr. 2004;80:271–8.
26. Shen W, Punyanitya M, Chen J, et al. Visceral adipose tissue: relationships between single slice areas at different locations and obesity-related health risks. Int J Obes (2005). 2007;31:763–9.
27. Fogelman DR, Holmes H, Mohammed K, et al. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014;5:307–13.
28. Barret M, Antoun S, Dalban C, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66:583–9.
29. Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. J Cachexia Sarcopenia Muscle. 2014.
30. Santa Mina D, Clarke H, Ritvo P, et al. Effect of totalbody prehabilitation on postoperative outcomes: a systematic review and meta-analysis. Physiotherapy. 2014;100:196–207.
31. de Campos-Ferraz PL, Andrade I, das Neves W, Hangai I, Alves CR, Lancha AH Jr. An overview of amines as nutritional supplements to counteract cancer cachexia. J Cachexia Sarcopenia Muscle. 2014;5:105–10.
32. Di Girolamo FG, Situlin R, Mazzucco S, Valentini R, Toigo G, Biolo G. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr MetabCare. 2014;17:145–50.
33. Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle. 2014;5:83–7.
34. Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656–66.
35. Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787–95.